FDA Approves Medtronic’s Abre Venous Stent
The approval is based on the results ABRE clinical study, which showed the stent improved patency iliofemoral veins in 88% of cases with a 2% rate of major adverse events.
You may also be interested in...
The deal gives Medtronic the exclusive right to acquire Half Moon Medical, a start-up developing a mitral valve repair system to compete with Abbott’s MitraClip.
The SMART trial will compare Medtronic’s Evolut TAVR systems to Edward’s Sapien 3 devices. Evolut EXPAND TAVR I will evaluate Evolut in patients with symptomatic moderate aortic stenosis or asymptomatic severe disease.
SELUTION SLR is the first drug-eluting balloon accepted by the FDA as part of its breakthrough program, according to the company.